SymBio Pharmaceuticals Limited

4582

JP3383050006

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 15/05/2024 am IST			5-day change	1st Jan Change
163 ^JPY	-1.21%		-4.12%	-34.01%

19/04	SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	CI
18/03	SymBio Pharmaceuticals Limited amended terms of the transaction	CI

Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022

August 04, 2022 at 12:00 pm IST

SymBio Pharmaceuticals Limited revised earning guidance for Fiscal year ending December 31, 2022. For the year company expects net sales to be JPY 10,003 million, Operating profit to be JPY 1,770 million, Profit attributable to owners of parent to be JPY 1,480 Million and earnings per share to be JPY 38.35 per share.

Latest news about SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	19/04	CI
SymBio Pharmaceuticals Limited amended terms of the transaction	18/03	CI
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	13/02	MT
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	08/02	CI
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	08/02	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	08/02	CI
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	15/11	MT
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	14/11	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	14/11	CI
SymBio Pharmaceuticals Limited amended terms of the transaction	10/11	CI
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC	06/23/06	CI
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	03/23/03	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	03/23/03	CI
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	27/23/27	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases	25/23/25	MT
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	24/23/24	CI
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	22/23/22	CI
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09/23/09	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	08/22/08	CI
Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022	08/22/08	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2022	04/22/04	CI
Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022	04/22/04	CI
SymBio Pharmaceuticals Limited announced that it has received ¥675.76 million in funding from CVI Investments, Inc.	01/22/01	CI
SymBio Pharmaceuticals Limited announced that it expects to receive ¥675.76 million in funding from CVI Investments, Inc.	16/22/16	CI

Chart SymBio Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYMBIO PHARMACEUTICALS LIMITED	-34.01%	48.31M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.79%	364B
MERCK & CO., INC.	+20.55%	326B
ABBVIE INC.	+5.55%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+11.02%	167B
PFIZER, INC.	+0.26%	161B

Other Pharmaceuticals